Country: Canada
Language: English
Source: Health Canada
GEMCITABINE (GEMCITABINE HYDROCHLORIDE)
ELI LILLY CANADA INC
L01BC05
GEMCITABINE
200MG
POWDER FOR SOLUTION
GEMCITABINE (GEMCITABINE HYDROCHLORIDE) 200MG
INTRAVENOUS
5ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0133122001; AHFS:
CANCELLED POST MARKET
2015-03-11
GEMZAR Product Monograph Page 1 of 52 PRODUCT MONOGRAPH Pr GEMZAR ® Gemcitabine Hydrochloride for Injection 200 mg or 1 g gemcitabine per vial Antineoplastic Agent © Eli Lilly Canada 3650 Danforth Ave. Toronto, Ontario M1N 2E8 1-888-545-5972 www.lilly.ca Date of Revision: April 28, 2014 Submission Control No. 171741 GEMZAR Product Monograph Page 2 of 52 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ................................................. 3 SUMMARY PRODUCT INFORMATION ................................................................ 3 INDICATIONS AND CLINICAL USE....................................................................... 3 CONTRAINDICATIONS ............................................................................................ 4 WARNINGS AND PRECAUTIONS .......................................................................... 4 ADVERSE REACTIONS ............................................................................................ 8 DRUG INTERACTIONS .......................................................................................... 20 DOSAGE AND ADMINISTRATION ...................................................................... 21 OVERDOSAGE ........................................................................................................ 24 ACTION AND CLINICAL PHARMACOLOGY ..................................................... 24 STORAGE AND STABILITY .................................................................................. 26 DOSAGE FORMS, COMPOSITION AND PACKAGING...................................... 26 PART II: SCIENTIFIC INFORMATION ....................................................................... 27 PHARMACEUTICAL INFORMATION .................................................................. 27 CLINICAL TRIALS .................................................................................................. 27 DETAILED PHARMACOLOGY ............................................................................. 38 TOXICOLOGY.......... Read the complete document